title: Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?
authors.forename: H
authors.initials: H
authors.lastname: Izzedine
authors.forename: D
authors.initials: D
authors.lastname: Sène
authors.forename: J
authors.initials: J
authors.lastname: Hadoux
authors.forename: C
authors.initials: C
authors.lastname: Gharbi
authors.forename: E
authors.initials: E
authors.lastname: Bourry
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: J C
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D057049:Thrombotic Microangiopathies / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A